文献速递糖尿病

益生菌、益生元或合生元对糖尿病患者代谢结局影响的系统综述与荟萃分析

The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis.
PubMed 文献 · Diabetologia · 2020-10-13

该系统综述与荟萃分析纳入38项随机对照临床试验,评估益生菌、益生元或合生元补充对糖尿病患者肠道菌群及糖脂代谢的影响。结果显示补充剂可降低空腹血糖、总胆固醇、甘油三酯和胰岛素水平,升高HDL胆固醇,但HbA1c降低未达显著性,LDL胆固醇无显著变化。结论认为其可能作为改善代谢结局的辅助治疗,但效应幅度较低。

要点

  • 补充益生菌/益生元/合生元可显著降低糖尿病患者空腹血糖、总胆固醇、甘油三酯和胰岛素水平。
  • HDL胆固醇显著升高,但HbA1c降低未达统计学显著性,LDL胆固醇无显著改变。
  • 效应幅度较低,可作为改善代谢结局的潜在辅助治疗。

核心结论

  • 在糖尿病患者中,补充益生菌、益生元或合生元可改善代谢指标,但效应幅度较低,可能作为辅助治疗。

研究设计与样本

  • 系统综述与随机效应荟萃分析,检索MEDLINE、EMBASE和Cochrane Library,最终纳入38项随机对照临床试验。

主要发现

  • HbA1c降低未达显著性:-2.17 mmol/mol(95%CI -4.37, 0.03;p=0.05;I2=66%),即-0.20%(95%CI -0.40, 0.00;p=0.05)。
  • 空腹血糖降低-0.58 mmol/l(95%CI -0.86, -0.30;p<0.01;I2=60%)。
  • 总胆固醇降低-0.14 mmol/l(95%CI -0.26, -0.02;p=0.02;I2=39%)。
  • 甘油三酯降低-0.11 mmol/l(95%CI -0.20, -0.02;p=0.01;I2=21%)。
  • 胰岛素水平降低-10.51 pmol/l(95%CI -16.68, -4.33;p<0.01;I2=74%),HDL胆固醇升高0.04 mmol/l(95%CI 0.01, 0.07;p<0.01;I2=24%)。

关键数值与推荐

  • LDL胆固醇无显著变化:-0.05 mmol/l(95%CI -0.14, 0.05;p=0.35;I2=37%)。

临床怎么用

  • 对于糖尿病患者,可考虑将益生菌、益生元或合生元作为改善空腹血糖和血脂谱的辅助措施,但需告知效应幅度较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim was to conduct a systematic review and meta-analysis of randomised controlled clinical trials assessing the effect of probiotic, prebiotic or synbiotic supplementation on gut microbiota and glucose control and lipid levels in individuals with diabetes. METHODS: MEDLINE, EMBASE and the Cochrane Library were searched. The eligibility criteria for the studies was involvement of participants with a diagnosis of type 1 or type 2 diabetes. Metabolic outcomes (glucose control, insulinaemia, and lipid profile) of any probiotic, prebiotic or synbiotic supplementation related to modification of gut microbiota (prebiotics, probiotics and synbiotics) were analysed. We provided a narrative synthesis and meta-analysis of the findings on metabolic outcomes from the studies. Metabolic outcomes were extracted post-intervention and expressed as mean differences (MDs) and 95% CIs between treatment and comparator groups. We pooled the results using a random-effects meta-analysis. The meta-analysis was conducted using Review Manager (RevMan) software. RESULTS: After the removal of duplicates and ineligible studies, 5219 studies were retained for review of titles and abstracts. The number of articles was reduced to 130 by review, for which the full-text articles were obtained and reassessed, 38 of which were included in the final meta-analysis. Overall, the use of prebiotics, probiotics or synbiotics reduced HbA1c levels, but did not reach the threshold for significance (-2.17 mmol/mol, 95% CI -4.37, 0.03; p = 0.05, [-0.20%, 95% CI -0.40 to 0.00; p = 0.05, I2 = 66%]) and had no effect on LDL-cholesterol levels (-0.05 mmol/l; 95% CI -0.14, 0.05, p = 0.35, I2 = 37%). However, their consumption decreased levels of fasting blood glucose (-0.58 mmol/l; 95% CI -0.86, -0.30; p < 0.01, I2 = 60%), total cholesterol (-0.14 mmol/l; 95% CI -0.26, -0.02, p = 0.02, I2 = 39%), triacylglycerols (-0.11 mmol/l; 95% CI -0.20, -0.02, p = 0.01, I2= 21%) and insulinaemia (-10.51 pmol/l; 95% CI -16.68,-4.33, p < 0.01, I2 = 74%), and increased HDL-cholesterol levels (0.04 mmol/l; 95% CI 0.01, 0.07, p < 0.01, I2= 24%). CONCLUSIONS/INTERPRETATION: In individuals with diabetes mellitus, supplementation with probiotics, prebiotics or synbiotics improved metabolic variables, although the magnitude of this effect is low. Our results suggest that consumption of probiotics, prebiotics or synbiotics may be a potential adjuvant treatment for improving metabolic outcomes. REGISTRATION: PROSPERO ID CRD42017080071. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bock PM, Telo GH, Ramalho R, et al. The effect of probiotics, prebiotics or synbiotics on metabolic outcomes in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2020. PMID: 33047170. doi:10.1007/s00125-020-05295-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。